Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 9/2015

01-09-2015 | Original Article – Clinical Oncology

A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection

Authors: Yusuke Okuma, Junko Tanuma, Hiroshi Kamiryo, Yuki Kojima, Mihoko Yotsumoto, Atsushi Ajisawa, Tomoko Uehira, Hirokazu Nagai, Yuichiro Takeda, Yasuhiro Setoguchi, Seiji Okada

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2015

Login to get access

Abstract

Purpose

Lung cancer has become a crucial problem among individuals living with the human immunodeficiency virus (HIV) and causes high mortality in Western countries. Japan has an increasing number of newly infected HIV patients, and lung cancer is becoming a theme in this population. However, clinical factors of this particular population in East Asian are unclear given the identification of ethnic differences in lung cancer in the general population.

Methods

From 1986 to 2013, a retrospective nationwide study involving Japanese patients living with HIV and diagnosed with lung cancer was undertaken.

Results

Forty-three lung cancer patients with HIV were identified (median age, 60.0 years; males, 97.7 %; early-stage cancer, 37.2 %; metastatic cancer, 34.9 %), 41 (95.3 %) of whom developed lung cancer in the antiretroviral era. The median CD4-positive T-cell count was 326 cells/µL. Adenocarcinoma was the most frequent histology (55.8 %), followed by squamous cell carcinoma (27.9 %). Epidermal growth factor receptor (EGFR) status was examined in 14 patients; five (35.7 %) had EGFR mutations. The median overall survival time was 25.1 months for all stages and 7.9 months for advanced-stage cancer. Using univariate analysis, the only favorable prognostic factor for overall survival was cancer stage (p = 0.02).

Conclusions

The incidence of lung cancer among HIV patients in Japan has been increasing in the past decade. The present Japanese cohort showed similar EGFR mutation status similar to that of general population. The ethnic differences known in the general population were seen even in the population living with HIV, implying distinct clinical characteristics and outcomes from those reported in Western countries.
Literature
Alshafie MT, Donaldson B, Oluwole SF (1997) Human immunodeficiency virus and lung cancer. Br J Surg 84:1068–1071CrossRefPubMed
Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25(10):1935–1940CrossRefPubMed
Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251–6266PubMedCentralCrossRefPubMed
Bertolaccini L, Lybéris P, Soncini S, Giovanni D, Emilpaolo M (2008) Clinical characteristic lung cancer in HIV-infected patients. Cancer Ther 6:903–906
Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, Gazzard B (2003) HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 17(3):371–375CrossRefPubMed
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465PubMedCentralCrossRefPubMed
Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, Keruly JC, Yang SC, Heitmiller RF, Baylin SB, Herman JG, Brahmer JR (2006) Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 43(1):47–55CrossRefPubMed
Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA (2007) Elevated risk of lung cancer among people with AIDS. AIDS 21(2):207–213CrossRefPubMed
Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(5):336–347CrossRefPubMed
Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–1440CrossRefPubMed
Clifford GM, Lise M, Franceschi S, Egger M, Bouchardy C, Korol D, Levi F, Ess S, Jundt G, Wandeler G, Fehr J, Schmid P, Battegay M, Bernasconi E, Cavassini M, Calmy A, Keiser O, Schoni-Affolter F, Swiss HIVCS (2012) Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 106(3):447–452PubMedCentralCrossRefPubMed
Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK, Wegner S (2009) Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 23(1):41–50PubMedCentralCrossRefPubMed
Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De Lisi V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomin A, Bellu F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligoi B, Franceschi S, Cancer, Study ARL (2009) Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 100(5):840–847PubMedCentralCrossRefPubMed
D’Jaen GA, Pantanowitz L, Bower M, Buskin S, Neil N, Greco EM, Cooley TP, Henry D, Stem J, Dezube BJ, Stebbing J, Aboulafia DM (2010) Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 11(6):396–404CrossRefPubMed
Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ, Study HACM (2006) Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 20(12):1645–1654CrossRefPubMed
Engsig FN, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Gerstoft J, Obel N (2011) Lung cancer in HIV patients and their parents: a Danish cohort study. BMC Cancer 11:272PubMedCentralCrossRefPubMed
Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gerard L, Oksenhendler E (2007) Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood 110(8):2846–2854CrossRefPubMed
Grubb JR, Moorman AC, Baker RK, Masur H (2006) The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 20(8):1095–1107CrossRefPubMed
Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, Le Marchand L (2006) Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 354(4):333–342CrossRefPubMed
Hakimian R, Fang H, Thomas L, Edelman MJ (2007) Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2(4):268–272CrossRefPubMed
Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig J, Mugavero M, Saag M, Martin JN, Deeks SG (2009) Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 48(6):787–794PubMedCentralCrossRefPubMed
Lanoy E, Spano JP, Bonnet F, Guiguet M, Boue F, Cadranel J, Carcelain G, Couderc LJ, Frange P, Girard PM, Oksenhendler E, Poizot-Martin I, Semaille C, Agut H, Katlama C, Costagliola D (2011) The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer 129(2):467–475CrossRefPubMed
Lavole A, Chouaid C, Baudrin L, Wislez M, Raguin G, Pialoux G, Girard PM, Milleron B, Cadranel J (2009) Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer 65(3):345–350CrossRefPubMed
Levine AM, Seaberg EC, Hessol NA, Preston-Martin S, Silver S, Cohen MH, Anastos K, Minkoff H, Orenstein J, Dominguez G, Watts DH (2010) HIV as a risk factor for lung cancer in women: data from the Women’s Interagency HIV study. J Clin Oncol 28(9):1514–1519PubMedCentralCrossRefPubMed
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388CrossRefPubMed
Makinson A, Pujol JL, Le Moing V, Peyriere H, Reynes J (2010) Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. J Thorac Oncol 5(4):562–571CrossRefPubMed
Massera F, Rocco G, Rossi G, Robustellini M, Pona CD, Meroni A, Rizzi A (2000) Pulmonary resection for lung cancer in HIV-positive patients with low (<200 lymphocytes/mm(3)) CD4(+) count. Lung Cancer 29(2):147–149CrossRefPubMed
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128CrossRefPubMed
Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, Easterbrook PJ (2008) Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther 5:23PubMedCentralCrossRefPubMed
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311(7010):899–909CrossRef
Okuma Y, Yanagisawa N, Takagi Y, Hosomi Y, Suganuma A, Imamura A, Iguchi M, Okamura T, Ajisawa A, Shibuya M (2012) Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection. Int J Clin Oncol 17(5):462–469CrossRefPubMed
Okuma Y, Yanagisawa N, Hosomi Y, Imamura A, Okamura T, Kato K, Negishi K (2013) Concomitant chemoradiotherapy and antiretroviral therapy for HIV-infected patients with locoregionally advanced non-small cell lung cancer: benefit and tolerability of treatment in 2 cases. Onkologie 36(10):586–590CrossRefPubMed
Oriol A, Ribera JM, Esteve J, Sanz MA, Brunet S, Garcia-Boyero R, Fernandez-Abellan P, Marti JM, Abella E, Sanchez-Delgado M, Penarrubia MJ, Besalduch J, Moreno MJ, Borrego D, Feliu E, Ortega JJ, Pethema Group SSoH (2003) Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 88(4):445–453PubMed
Oriol A, Ribera JM, Brunet S, del Potro E, Abella E, Esteve J (2005) Highly active antiretroviral therapy and outcome of AIDS-related Burkitt’s lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 90(7):990–992PubMed
Ou SH, Ziogas A, Zell JA (2009) Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 4(9):1083–1093CrossRefPubMed
Pakkala S, Ramalingam SS (2010) Lung cancer in HIV-positive patients. J Thorac Oncol 5(11):1864–1871CrossRefPubMed
Pakkala S, Chen Z, Rimland D, Owonikoko TK, Gunthel C, Brandes JR, Saba NR, Shin DM, Curran WJ Jr, Khuri FR, Ramalingam SS (2012) Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 118(1):164–172PubMedCentralCrossRefPubMed
Petoumenos K, Hui E, Kumarasamy N, Kerr SJ, Choi JY, Chen YM, Merati T, Zhang F, Lim PL, Sungkanuparph S, Pujari S, Ponnampalavanar S, Ditangco R, Lee CK, Grulich A, Law MG, Database TAHO (2010) Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factors. J Int AIDS Soc 13(1):51PubMedCentralCrossRefPubMed
Rengan R, Mitra N, Liao K, Armstrong K, Vachani A (2012) Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol 13(12):1203–1209CrossRefPubMed
Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA (2015) Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 107(4):dju503. doi:10.​1093/​jnci/​dju503
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M, Spanish Lung Cancer G (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–967CrossRefPubMed
Samet JM, Wiggins CL, Humble CG, Pathak DR (1988) Cigarette smoking and lung cancer in New Mexico. Am Rev Respir Dis 137(5):1110–1113CrossRefPubMed
Sanchez X, Cousins-Hodges B, Aguilar T, Gosselink P, Lu Z, Navarro J (1997) Activation of HIV-1 coreceptor (CXCR4) mediates myelosuppression. J Biol Chem 272(44):27529–27531CrossRefPubMed
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550CrossRefPubMed
Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT, Centers for Disease Control and Prevention (2008) Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years–United States, 2008. MMWR Recomm Rep 57(RR-10):1–12PubMed
Setiawan VW, Haiman CA, Stanczyk FZ, Le Marchand L, Henderson BE (2006) Racial/ethnic differences in postmenopausal endogenous hormones: the multiethnic cohort study. Cancer Epidemiol Biomark Prev 15(10):1849–1855CrossRef
Sigel K, Crothers K, Dubrow R, Krauskopf K, Jao J, Sigel C, Moskowitz A, Wisnivesky J (2013) Prognosis in HIV-infected patients with non-small cell lung cancer. Br J Cancer 109(7):1974–1980PubMedCentralCrossRefPubMed
Spano JP, Massiani MA, Bentata M, Rixe O, Friard S, Bossi P, Rouges F, Katlama C, Breau JL, Morere JF, Khayat D, Couderc LJ (2004) Lung cancer in patients with HIV Infection and review of the literature. Med Oncol 21(2):109–115CrossRefPubMed
Spitsin S, Tustin NB, Riedel E, Tustin R III, Murray JB, Peck LM, Khan M, Quinn J, Douglas SD (2012) Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy. Clin Vaccine Immunol 19(5):752–756PubMedCentralCrossRefPubMed
Sridhar KS, Flores MR, Raub WA Jr, Saldana M (1992) Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects. Chest 102(6):1704–1708CrossRefPubMed
Tirelli U, Spina M, Sandri S, Serraino D, Gobitti C, Fasan M, Sinicco A, Garavelli P, Ridolfo AL, Vaccher E (2000) Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 88(3):563–569CrossRefPubMed
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454PubMedCentralCrossRefPubMed
Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A (2003) Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 98(6):1196–1205CrossRefPubMed
White CS, Haramati LB, Elder KH, Karp J, Belani CP (1995) Carcinoma of the lung in HIV-positive patients: findings on chest radiographs and CT scans. AJR Am J Roentgenol 164(3):593–597CrossRefPubMed
Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM, Minna JD, Gazdar AF (1998) Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 279(19):1554–1559CrossRefPubMed
Metadata
Title
A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection
Authors
Yusuke Okuma
Junko Tanuma
Hiroshi Kamiryo
Yuki Kojima
Mihoko Yotsumoto
Atsushi Ajisawa
Tomoko Uehira
Hirokazu Nagai
Yuichiro Takeda
Yasuhiro Setoguchi
Seiji Okada
Publication date
01-09-2015
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-015-1956-8

Other articles of this Issue 9/2015

Journal of Cancer Research and Clinical Oncology 9/2015 Go to the issue

Original Article – Clinical Oncology

Incidence, treatment, and outcome of parotid carcinoma, 1996–2011: a population-based study in Thuringia, Germany

Original Article – Clinical Oncology

A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy

Original Article – Cancer Research

Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese

Original Article – Clinical Oncology

Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma

Original Article – Cancer Research

Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15

Original Article – Cancer Research

Expression pattern of autophagy-related markers in non-metastatic clear cell renal cell carcinoma: association with disease recurrence following radical nephrectomy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits